ClinicalTrials.gg
CompletedNCT01135498Updated Feb 6, 2015Results posted

A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.

A Phase 2 interventional study of bevacizumab [Avastin] and eloxatin in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 12 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-02-06.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 230 studies testing bevacizumab in Colorectal Neoplasms — 49 open to participants now, 61 under way, 11 of them phase 3. Bevacizumab · Colorectal Neoplasms.

Enrollment
87th of 224
90 · median 63
Started
2006
with 24 others
Phase 2
133 of 230
31 open now
Registered
89th of 230
by date
Lead sponsor
22 of 230
Hoffmann-La Roche

Among the 230 studies testing bevacizumab in Colorectal Neoplasms, this one is the 87th largest by enrollment of the 224 interventional ones that give a count, is one of 25 that started in 2006, is one of 133 in phase 2, and was the 89th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

49 of the 230 studies testing bevacizumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

44 more — sign in →

By country, each count listing its studies:

All 49 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies testing bevacizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of a first-line regimen of Avastin and Xelox (Xeloda + Eloxatin) followed by Avastin and Tarceva, in patients with metastatic colorectal cancer. Patients will receive 6 x 21 day cycles of treatment with Avastin (7.5mg/kg iv on day 1), Xeloda (1000mg/m2 po twice daily on days 1 to 14) and Eloxatin (130mg/m2 iv on day 1). Patients free of disease progression will then continue with Avastin (7.5mg/kg iv once every 3 weeks) and Tarceva (150mg po daily). The anticipated time on study treatment is until disease progression, and the target sample size is \<100 individuals.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • adenocarcinoma of colon or rectum, with disease;
  • >=1 .

Exclusion criteria

Exclusion Criteria:

  • previous treatment with Avastin or Tarceva;
  • previous systemic treatment for advanced or disease;
  • treatment for non-metastatic disease in past 6 months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    1

    Drug: bevacizumab [Avastin] · Drug: eloxatin · Drug: capecitabine [Xeloda] · Drug: erlotinib [Tarceva]

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Disease Progression or Death

    Disease progression was defined according to Response Evaluation Criteria in Solid Tumors (RECIST) as a 20 percent (%) increase in the sum of the longest diameter of target lesions, or a measureable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: Start of study to approximately 4 years

  2. Progression-Free Survival

    Progression-free survival was defined as the time from the date of informed consent until the date when the participant had progression of disease or died from disease progression. Participants who received surgical treatment after treatment ended were censored at the time of surgery. Participants who left the study for reasons other than progression of the disease were censored on the date on which they received a later antitumor therapy (with the same or different drugs, radiotherapy, or surgery).

    Time frame: From study start up to approximately 4 years

Secondary outcomes

  1. Percentage of Participants Achieving Objective Response (Complete Response [CR] or Partial Response [PR])

    Percentage of participants with objective response based assessment of CR or PR according to Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than \[\<\]10 millimeters \[mm\]) and no new lesions. PR was defined as greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

    Time frame: From study start up to approximately 4 years

  2. Percentage of Participants Achieving Disease Control (CR, PR, or No Change [NC])

    Percent of participants with confirmed CR, PR, or NC. Per RECIST version (v)1.0: CR was defined as disappearance of all target and non-target lesions. PR was defined as ≥30% decrease in sum of longest diameters of target lesions taking as reference baseline sum longest diameters associated to non-progressive disease response for non-target lesions. NC was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease taking as reference smallest sum of longest dimensions since treatment started associated to non-progressive disease response for non-target lesions.

    Time frame: From study start up to approximately 4 years

  3. Percentage of Participants Who Died

    Time frame: From study start up to approximately 4 years

  4. Overall Survival (OS)

    Overall survival was defined as the time from the date of informed consent to the date of death (regardless of the cause of death). There was no restriction; survival was calculated until the date of death, even if another line of treatment was received, or until the date censored (last contact with the participant even if drugs different from the study treatment schedule were received). For all participants, survival information was collected until the date of death, the last contact, or the last follow-up.

    Time frame: From study start up to approximately 4 years

07

Results

Posted Feb 6, 2015

Participant flow

Participant flow — Overall Study
MilestoneBevacizumab+Oxaliplatin+Capecitabine/Bevacizumab+Erlotinib
Started90
Completed0
Not completed90
Withdrew: Adverse event20
Withdrew: Progressive disease38
Withdrew: Investigator judgement25
Withdrew: Withdrawal by subject4
Withdrew: Death1
Withdrew: Ongoing at time of analysis2

Outcome measures

PrimaryPercentage of Participants With Disease Progression or Death

Disease progression was defined according to Response Evaluation Criteria in Solid Tumors (RECIST) as a 20 percent (%) increase in the sum of the longest diameter of target lesions, or a measureable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
Start of study to approximately 4 years
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Progression or Death
percentage of participantsBevacizumab+Oxaliplatin+Capecitabine/Bevacizumab+Erlotinib
Percentage of Participants With Disease Progression or Death61.1
SecondaryPercentage of Participants Achieving Objective Response (Complete Response [CR] or Partial Response [PR])

Percentage of participants with objective response based assessment of CR or PR according to Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than \[\<\]10 millimeters \[mm\]) and no new lesions. PR was defined as greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

Time frame:
From study start up to approximately 4 years
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Objective Response (Complete Response [CR] or Partial Response [PR])
percentage of participantsBevacizumab+Oxaliplatin+Capecitabine/Bevacizumab+Erlotinib
Percentage of Participants Achieving Objective Response (Complete Response [CR] or Partial Response [PR])55.95
SecondaryPercentage of Participants Achieving Disease Control (CR, PR, or No Change [NC])

Percent of participants with confirmed CR, PR, or NC. Per RECIST version (v)1.0: CR was defined as disappearance of all target and non-target lesions. PR was defined as ≥30% decrease in sum of longest diameters of target lesions taking as reference baseline sum longest diameters associated to non-progressive disease response for non-target lesions. NC was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease taking as reference smallest sum of longest dimensions since treatment started associated to non-progressive disease response for non-target lesions.

Time frame:
From study start up to approximately 4 years
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Disease Control (CR, PR, or No Change [NC])
percentage of participantsBevacizumab+Oxaliplatin+Capecitabine/Bevacizumab+Erlotinib
Percentage of Participants Achieving Disease Control (CR, PR, or No Change [NC])92.86
SecondaryPercentage of Participants Who Died
Time frame:
From study start up to approximately 4 years
Reported as:
Number · percentage of participants
Percentage of Participants Who Died
percentage of participantsBevacizumab+Oxaliplatin+Capecitabine/Bevacizumab+Erlotinib
Percentage of Participants Who Died58.89
PrimaryProgression-Free Survival

Progression-free survival was defined as the time from the date of informed consent until the date when the participant had progression of disease or died from disease progression. Participants who received surgical treatment after treatment ended were censored at the time of surgery. Participants who left the study for reasons other than progression of the disease were censored on the date on which they received a later antitumor therapy (with the same or different drugs, radiotherapy, or surgery).

Time frame:
From study start up to approximately 4 years
Reported as:
Median · months
Progression-Free Survival
monthsBevacizumab+Oxaliplatin+Capecitabine/Bevacizumab+Erlotinib
Progression-Free Survival9.18 (7.86 to 11.87)
SecondaryOverall Survival (OS)

Overall survival was defined as the time from the date of informed consent to the date of death (regardless of the cause of death). There was no restriction; survival was calculated until the date of death, even if another line of treatment was received, or until the date censored (last contact with the participant even if drugs different from the study treatment schedule were received). For all participants, survival information was collected until the date of death, the last contact, or the last follow-up.

Time frame:
From study start up to approximately 4 years
Reported as:
Median · months
Overall Survival (OS)
monthsBevacizumab+Oxaliplatin+Capecitabine/Bevacizumab+Erlotinib
Overall Survival (OS)25.79 (17.99 to 30.92)

Adverse events

Collected over Participants were monitored for adverse events (AEs) from the first dose of study drug until the end of the study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib—33/90 (36.7%)89/90 (98.9%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventBevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib
DiarrhoeaGastrointestinal disorders18/90
AstheniaGeneral disorders11/90
NeutropeniaBlood and lymphatic system disorders7/90
RashSkin and subcutaneous tissue disorders6/90
VomitingGastrointestinal disorders4/90
HypertensionVascular disorders4/90
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/90
AcneSkin and subcutaneous tissue disorders3/90
Deep vein thrombosisVascular disorders3/90
AnaemiaBlood and lymphatic system disorders2/90
Most frequent other events
Showing 10 of 200
Most frequent other events
EventBevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib
AstheniaGeneral disorders69/90
DiarrhoeaGastrointestinal disorders56/90
NauseaGastrointestinal disorders41/90
RashSkin and subcutaneous tissue disorders38/90
VomitingGastrointestinal disorders36/90
AnorexiaMetabolism and nutrition disorders35/90
ParaesthesiaNervous system disorders35/90
NeurotoxicityNervous system disorders32/90
Abdominal painGastrointestinal disorders31/90
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders29/90

Baseline characteristics

Intent-to-treat (ITT) population: all enrolled participants.

Age, Continuous
Age, Continuous(years)Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab+Erlotinib
Mean59.23 ± 8.18
Sex: Female, Male
Sex: Female, Male(Participants)Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab+Erlotinib
Female29
Male61
08

Study locations

12 sites
  • Sabadell, Barcelona, Barcelona 08208, Spain
  • Terrassa, Barcelona 08221, Spain
  • Santander, Cantabria 39008, Spain
  • Palma de Mallorca, Islas Baleares 07198, Spain
  • Logroño, La Rioja 26006, Spain
  • Barakaldo, Vizcaya 48903, Spain
  • Burgos, 09006, Spain
  • Huesca, 22004, Spain
  • Jaen, 23007, Spain
  • Lerida, 25198, Spain
  • Teruel, 44002, Spain
  • Zaragoza, 50009, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 4 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2010
First posted
Jun 2, 2010
Start
Nov 2006
Primary completionActual
Apr 2010
CompletionActual
Apr 2010
Results first posted
Feb 6, 2015
Last update
Feb 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01135498
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 2, 2010
Start date
Nov 2006
Primary completion
Apr 2010
Completion
Apr 2010
Results posted
Feb 6, 2015
Last update
Feb 6, 2015

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Oxaliplatin · Capecitabine · Erlotinib

Start the discussion